APP and Alzheimer disease: In EOAD patients, these pathological findings could be fully explained by the mutations detected in different genes involved in APP synthesis and metabolism (APP, PS1, and/or PS2 genes) [15,16], and supported by the findings in transgenic mice, expressing at least one of these human mutated genes, that showed the same peculiar cerebral amyloid pathology of AD subjects [17,18].